Dr. Lal Path Labs Ltd. has informed the Exchange about Transcript
LALPATHLAB · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Dr. Lal PathLabs reported a strong start to FY26 with Q1 revenue of Rs. 670 crore, up 11.3% year-on-year, and profit after tax of Rs. 134 crore, up 24.3%. EBITDA margin came in healthy at 28.7% (vs Rs. 192 crore), driven by a favourable test mix and SwasthFit bundle testing, which contributed 27% of revenue. Sample volumes grew 10.7% to 23.4 million and revenue per patient rose 5.7% to Rs. 880. The board declared an interim dividend of Rs. 6 per share (60%), and the company sits on a robust net cash position of Rs. 1,389 crore. Management maintained its 11-12% revenue growth guidance and indicated that full-year margins may come in slightly better than its earlier projection of up to 100 bps compression, given the strong Q1 performance and most reinvestments being back-loaded into H2.
Positive for shareholders — strong earnings beat, higher dividend, and an upward revision of margin outlook reinforce confidence in profitability despite reinvestment plans. The West region remains a near-term drag due to the ongoing Suburban IT integration, which is a key watchpoint for the next couple of quarters.